Lokhu kuhlola kuthola izibalo ze-autoantibodies ezisiza ukuqinisekisa ukuxilongwa
Ukuhlolwa kwe-anti-CCP kusetshenziselwa ukuthola ama-autoantibodies nosizo ukuhlukanisa phakathi kwesifo samathambo kanye nezinye izinhlobo zokuvuvukala kwamathambo . I-antibody ye-cyclic citrullinated peptide (CCP) i-autoantibody ngokumelene namaprotheni anesigodi (ACPA) futhi ilinganiswa nalolu vavanyo.
Ukuhlolwa kunomqondo ophakeme kakhulu we- arthritis ye- rheumatoid , kubikwa ukuthi phakathi kwamaphesenti angu-50 no-75.
Ibuye ibe nokucaca okuphezulu kakhulu kwe-arthritis ye-rheumatoid engamaphesenti angaba ngu-90. Ukucaca kwayo okuphezulu ukuthi kungani ukuhlolwa kwe-anti-CCP sekuyingxenye ebalulekile yenqubo yokuxilonga ye-arthritis ye-rheumatoid.
I-Anti-CCP Ukuhlola Ukuhlola Nokulinganisa Ukulinganiswa
Ngaphandle kokusiza ukuhlukanisa phakathi kwezinhlobo zokuvuvukala kwe-arthritis , ukuhlolwa kwe-anti-CCP nakho kuyigugu kakhulu ekuhloleni abantu abasebenzisa i- seronegative ngesici se-rheumatoid . Ukuhlolwa kwe-anti-CCP akukona nje ukuthi kunenani lokuhlonza (ukucacisa ukuthi ngabe unjani isimo), futhi sinenani lokubikezela (ukubikezela inkambo yesimo sakho).
Uma i-anti-CCP ikhona ngokulinganisela kuya ezingeni eliphakeme, akusizi nje kuphela ukuqinisekisa ukuxilongwa, kuphakamisa ukuthi kungase kube yinkambo eyingozi kakhulu yesifo, njengokulimala okuhlangene okuqhubekayo. Amazinga aphansi e-antibody awasho njengokutshela noma ukubikezela.
Ngokujwayelekile, ukuhlolwa kwe-anti-CCP kuyalwe kanye nokuhlolwa kwesici se-rheumatoid, ngoba ukuhlola kuphela okungaqinisekisile ukuxilongwa kwesifo samathambo.
Ngokwe-rheumatologist uScott J. Zashin, "Nakuba isifo sofuba sivame kakhulu kubantu abane-arthritis ye-rheumatoid, kukhona abantu abanesifo esihle se-rheumatoid abangenayo i-arthritis ye-rheumatoid. Ngaphezu kwalokho, ukutholakala kwesifo se-rheumatoid kunesibalo sokubikezela okuncane kune-ACPA.
Futhi, uma umuntu engenayo isifo se-rheumatoid, angenakwenzeka ukuba abe ne-ACPA. "
Ukukhomba ama-Autoantibodies
Ukubaluleka kokukhomba i-autoantibodies ngezifo ze-rheumatic bekuye kwaqaphela amashumi eminyaka, kepha ukukhomba labo ababenempilo ngokuqondene nobuchwepheshe nokuzwela kuthatha isikhathi. Kube nezizukulwane ezintathu zohlolo lwe-anti-CCP. Ngesizukulwane ngasinye sokuhlola okucacile nokuzwela kuye kwathuthukiswa.
Ngokusho kwe "Kelley's Textbook of Rheumatology," abangaphezu kwamaphesenti angu-90 abantu abane -arthritis engafaneleki abahlola ukuthi i-anti-CCP ihlakulela isifo samathambo phakathi neminyaka emithathu. Ngamaphesenti angama-25 kuphela alabo abanesifo samathambo angenakuphikisana abahlola okungalungile kwe-anti-CCP bakhule imishanguzo ye-rheumatoid arthritis.
Ama-autoantibodies angase abonakale ngaphambi kokuqala kwemitholampilo yezifo ezithile ezizimele, kuhlanganise ne-arthritis ye-rheumatoid. Ama-autoantibodies angaphambi kokuqala kwamathambo e-sophisticated rheumatoid iminyaka emibili kuya kweyisithupha, ngokusho "Kelley's Textbook of Rheumatology." Kubikwa ukuthi i-anti-CCP elinganiselwe esandulele ukuxilongwa kwe-arthritis ye-rheumatoid iphindwe kabili njengento ebonakalayo ye-rheumatoid esandulele ukuxilongwa.
Nakuba i-rheumatoid factor ngokuvamile ihlala ikhona njalo, ukutholakala kwe-anti-CCP kungashintsha iziguli zesifo se-rheumatoid arthritis-ngisho nokunyamalala kwezinye izimo.
Ukubaluleka kwe-Anti-CCP
Abacwaningi baqhubeka babheka okwenzeka emzimbeni ukukhiqiza ama-molecule (ama-antigens) abangela ukukhiqizwa kwala ma antiboxy-anti-CCP. Zibizwa ngokuthi i-autoantigens ngoba zikhiqizwa ukuwohloka kwezingxenye zomzimba kunokuba zivela ngaphandle komzimba. Ama-enzyme e-Peptidylarginine deiminase (PAD), okwenza ukuba ukuguqulwa kwe-peptidylarginine ibe yi-peptidylcitrulline, kunendima ebalulekile ekukhiqizeni ama-autoantigens ku-arthritis ye-rheumatoid.
Futhi, ucwaningo olwengeziwe luyadingeka ukuze kubone ukuthi yini ebangela isigaba sokuqala sesifo se-rheumatoid arthritis ukuba sishintshe esimweni sesifo, esinesifo esigcwele.
Ngenkathi i-anti-CCP iqondene kakhulu ne-arthritis ye-rheumatoid, imiphumela emihle ingase ivele nezinye izifo ezibangelwa yi-rheumatic, isifo sofuba nesifo sengculazi esingapheli. Ama-antibodies e-anti-CCP abike ku- systic lupus erythematosus nesifo se-Sjogren esiyinhloko, ngokuvamile lapho i-arthritis enamandla ekhona. Kuye kwafunyanwa ngamaphesenti angama-16 abantu abane- arthritis ye-psoriatic- ikakhulukazi nge-erosive noma i- polyarthritis . Ngezinye izikhathi, ihamba ne-psoriasis enamandla ngaphandle kwe-arthritis.
> Imithombo:
> Cush JJ, Kavanaugh A, Weinblatt ME. I-Arthritis Ye-Rheumatoid: Ukuxilongwa Kwangaphambili Nokunakekelwa . West Islip, NY: Ukuxhumana kobuchwepheshe; 2010.
> Firestein GS, uKelley WN. I-Kelleys Textbook ye-Rheumatology . Philadelphia, PA: Elsevier / Saunders; 2013.
> I-Taylor PC, i-Maintenance RN. Ama-Biologic Markers ekuHlangeni Nokuhlolwa Kwe-Rheumatoid Arthritis. Kusesikhathini. https://www.uptodate.com/contents/biologic-markers-in-the-diagnosis-and-assessment-of-rheumatoid-arthritis.